Aspergillosis of lung
ICD-10 B48.3 is a billable code used to indicate a diagnosis of aspergillosis of lung.
Aspergillosis of the lung is a fungal infection caused by the Aspergillus species, primarily Aspergillus fumigatus. This condition can manifest in various forms, including allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), and invasive aspergillosis. Patients with compromised immune systems, such as those with HIV/AIDS, cancer, or those undergoing immunosuppressive therapy, are at a higher risk for developing this infection. Symptoms may include cough, hemoptysis, fever, and chest pain. Diagnosis typically involves imaging studies such as chest X-rays or CT scans, along with microbiological cultures or serological tests. Treatment often includes antifungal medications such as voriconazole or amphotericin B, depending on the severity and type of aspergillosis. Early diagnosis and appropriate antifungal therapy are crucial for improving patient outcomes, especially in immunocompromised individuals.
Detailed clinical notes on respiratory symptoms, imaging results, and treatment plans.
Patients presenting with chronic cough, hemoptysis, or recurrent pneumonia.
Ensure clear documentation of lung involvement and any underlying lung diseases.
Comprehensive history of immunocompromised conditions, laboratory results, and treatment response.
Patients with a history of organ transplantation or chemotherapy presenting with respiratory symptoms.
Document the type of antifungal therapy and any adverse reactions.
Used for outpatient management of aspergillosis.
Document the indication for therapy and response to treatment.
Pulmonologists should document the patient's clinical status and any side effects.
The primary treatment for aspergillosis of the lung typically involves antifungal medications such as voriconazole or amphotericin B, depending on the type and severity of the infection.
